Clinical trial · Observational
A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells
A Long Term Follow-Up Study for Subjects Who Have Received Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) (LTFU Study)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is an observational study designed to obtain information on the long-term safety, tolerability, and continued activity of Q-Cells®. The study will follow the participants who previously received Q-Cells® for 10 years. The goal of this observational study is to learn about the long term effects of Q-Cells® in people with transverse myelitis. The main objectives the study is to evaluate the safety of patients who have received Q-Cells®. The secondary goal of the study is to get data about the long-term activity of Q-Cells® over a period of 10 years. Patients will complete exams, lab tests, imaging, and questionnaires to monitor their safety.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Transverse Myelitis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Q-Cells® | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cohort 1: 10 microliters of Q cells
- description
- 10 microliters of Q cells per site
- interventionNames
- Drug: Q-Cells®
- label
- Cohort 2: 15 microliters of Q cells
- description
- 15 microliters of Q cells per site
- interventionNames
- Drug: Q-Cells®
- label
- Cohort 3: 20 microliters of Q cells
- description
- 20 microliters of Q cells per site
- interventionNames
- Drug: Q-Cells®
Primary outcomes (8)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Subjects must have been administered Q-Cells® as part of Protocol QTM-101 or other treatment Protocol. 2. Subjects must have the ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to collect and use protected health information (PHI) in accordance with national and local subject privacy regulations. Exclusion Criteria: 1\. The study is intended to follow all subjects who have received Q-Cells® without exception.
References
Publications (0)
Data not yet available